Menu
Summary:
In this trial, Dr. Forrest and team are using a dual immunotherapy approach to treat pediatric patients with recurrent or relapsed INI1-negative cancers. This group of cancers is both rare and aggressive, resulting in a poor prognosis for these children. Currently, there is no standard of care. If the study is successful, it will establish the proposed dual immunotherapy approach as the standard of care for children with recurrent or relapsed INI1-negative cancers.
Don't miss out on exciting news, helpful resources, and impactful stories delivered to your inbox each month.
20 North Martingale Road
Suite 180
Schaumburg, IL 60173
888-221-CURE
© 2022 Gateway for Cancer ResearchSM